News Releases Year None2022202120202019201820172016 Sep 07, 2022 Leap Therapeutics to Participate at the Baird 2022 Global Healthcare Conference Sep 06, 2022 Leap Therapeutics Announces Appointment of Richard L. Schilsky, MD to its Board of Directors Sep 04, 2022 Leap Therapeutics to Present New Data from DisTinGuish Study of DKN-01 Plus Tislelizumab and WAKING Study of DKN-01 Plus Tecentriq® at the ESMO Congress Aug 12, 2022 Leap Therapeutics Reports Second Quarter 2022 Financial Results Aug 12, 2022 Leap Therapeutics' Board of Directors Member Dr. Monica Bertagnolli Appointed as the Director of the National Cancer Institute Jul 12, 2022 Leap Therapeutics Announces Initiation of New DKN-01 Clinical Trials in Gastric Cancer, Colorectal Cancer and Endometrial Cancer Jun 27, 2022 Leap Therapeutics to Host Virtual R&D Day on July 12, 2022 May 26, 2022 Leap Therapeutics to Present Initial Data from the Investigator-Sponsored Study of DKN-01 Plus Docetaxel in Patients with Prostate Cancer at the 2022 ASCO Annual Meeting May 13, 2022 Leap Therapeutics Reports First Quarter 2022 Financial Results Mar 11, 2022 Leap Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results Current page 1 Page 2 Next page › Last page »
